对于抗血栓治疗而言，凝血因子Xa是比凝血因子IIa更理想的靶点。 - Suppr | 超能文献

Factor Xa is a superior target to factor IIa for antithrombotic therapies.

作者信息

Büller Harry R

机构信息

Department of Vascular Medicine, Academic Medical Center University of Amsterdam, The Netherlands.

出版信息

Semin Thromb Hemost. 2003 Dec;29 Suppl 1:37. doi: 10.1055/s-2003-45416.

DOI:10.1055/s-2003-45416

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Factor Xa is a superior target to factor IIa for antithrombotic therapies.对于抗血栓治疗而言，凝血因子Xa是比凝血因子IIa更理想的靶点。

Semin Thromb Hemost. 2003 Dec;29 Suppl 1:37. doi: 10.1055/s-2003-45416.

2

Factor Xa inhibitors: today and beyond.凝血因子Xa抑制剂：现状与未来。

Curr Opin Investig Drugs. 2003 Mar;4(3):272-81.

3

Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?为什么在凝血的治疗性抑制中，因子Xa不是比因子IIa更好的靶点？

Semin Thromb Hemost. 2003 Dec;29 Suppl 1:33-6. doi: 10.1055/s-2003-45415.

4

Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.在兔实验性血栓形成模型中比较两种肝素片段PK 10169（分子量5000）、EMT 680（分子量2500）和普通肝素的抗血栓活性：全身抗Xa和抗IIa活性的相对重要性

Nouv Rev Fr Hematol (1978). 1986;28(6):355-8.

5

Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.肝素治疗实验室监测的局限性。科学与标准化委员会通讯：代表国际血栓与止血学会科学与标准化委员会抗凝控制小组委员会。

Thromb Haemost. 2002 Jan;87(1):163-4.

6

[Where to look for progress in antithrombotic treatments?].[抗血栓治疗的进展方向何在？]

Rev Prat. 1999 Oct 1;49(15):1664-8.

7

The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins.抗Xa和抗IIa活性对低分子量肝素纤溶活性的作用。

Thromb Haemost. 2009 Apr;101(4):782-5.

8

Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations.抗凝血因子IIa检测方法的验证及药物制剂中依诺肝素的效价评估。

Farmaco. 2005 Mar;60(3):225-9. doi: 10.1016/j.farmac.2004.12.006.

9

Factor Xa inhibitors: next-generation antithrombotic agents.凝血因子Xa抑制剂：新一代抗血栓药物。

J Med Chem. 2010 Sep 9;53(17):6243-74. doi: 10.1021/jm100146h.

10

An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.一种藻类硫酸化半乳聚糖对静脉血栓形成具有不同寻常的双重作用，这是由于它激活了因子XII并抑制了凝血蛋白酶。

Thromb Haemost. 2008 Mar;99(3):531-8. doi: 10.1160/TH07-10-0649.

引用本文的文献

1

Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.尽管进行了皮下注射低分子量肝素、阿司匹林、氯吡格雷和阿昔单抗预处理，但在急性ST段抬高型心肌梗死的直接经皮冠状动脉介入治疗期间仍发生了导管血栓形成。

Can J Cardiol. 2006 May 1;22(6):511-5. doi: 10.1016/s0828-282x(06)70271-9.